文献速递类风湿关节炎

类风湿关节炎患者靶向治疗后主要不良心血管事件风险:按心血管风险分层的真实世界分析

Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk.
PubMed 文献 · Semin Arthritis Rheum · 2025-04-09

基于韩国全国医保数据库纳入2015至2019年接受JAK抑制剂(JAKi)或TNF抑制剂(TNFi)的7575例类风湿关节炎患者,按心血管风险分层并以倾向性评分匹配。高心血管风险组JAKi相比TNFi的主要不良心血管事件(MACE)风险比为0.77(95%CI 0.45-1.34),低心血管风险组及有无心血管病史亚组均未见显著差异。

要点

  • 高心血管风险组JAKi相比TNFi的MACE风险比0.77(95%CI 0.45-1.34)。
  • 低心血管风险组及有无心血管病史亚组JAKi与TNFi间MACE无显著差异。
  • 亚组和敏感性分析显示心肌梗死、卒中、心衰等单项MACE组分风险无统计学显著差异。

核心结论

  • 在不同心血管风险组及有无心血管病史的患者中,JAKi与TNFi使用者的MACE风险未见显著差异。
  • 亚组和敏感性分析支持上述发现,单项MACE组分未见风险升高。

研究设计与样本

  • 使用韩国全国医保索赔数据库,识别2015年至2019年间处方JAKi或TNFi的类风湿关节炎患者。
  • 按心血管风险分为两组,并在每组内以倾向性评分匹配,比例最高为1:4。
  • 随访持续至MACE、死亡或治疗终止,采用Cox比例风险模型计算风险比及95%置信区间。
  • 另在有无心血管病史的患者中分别分析MACE风险。

主要发现

  • 共纳入7575例处方JAKi或TNFi的患者。
  • 倾向性评分匹配后,高心血管风险组JAKi相比TNFi的MACE风险比为0.77(95%CI 0.45-1.34)。
  • 低心血管风险组以及有无心血管病史组中,JAKi与TNFi使用者间MACE均未见显著差异。
  • 亚组和敏感性分析显示心肌梗死、卒中、心力衰竭等单项MACE组分风险无统计学显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risk of major adverse cardiovascular events (MACEs) associated with Janus kinase inhibitors (JAKi) compared to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). METHODS: Using the Korean nationwide claims database, we identified patients with RA prescribed JAKi or TNFi between 2015 and 2019. Patients were stratified into two groups based on cardiovascular (CV) risk and matched within each group using propensity score matching at a ratio of up to 1:4. Follow-up continued until MACE, death, or treatment discontinuation. Hazard ratios with 95 % confidence intervals were calculated using the Cox proportional hazards model. Additionally, MACE risk was analyzed separately in patients with and without a history of cardiovascular disease (Hx.CVD). RESULTS: A total of 7575 patients prescribed either JAKi or TNFi were included. After propensity score matching, the hazard ratio for MACEs comparing JAKi to TNFi was 0.77 (95 % confidence interval 0.45-1.34) in the high CV risk group. No significant differences in MACEs were observed between JAKi and TNFi users across the low CV risk group, as well as Hx.CVD and non-Hx.CVD groups. Subgroup and sensitivity analyses showed no statistically significant differences in the risk of individual MACE components, such as myocardial infarction, stroke, or heart failure. CONCLUSION: No significant differences in the risk of MACEs were observed between JAKi and TNFi users across various CV risk groups and in those with or without Hx.CVD. Subgroup and sensitivity analyses supported these findings, showing no elevated risks for individual MACE components.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. You SH, Cho SK, Kim JY, et al. Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk. Semin Arthritis Rheum. 2025. PMID: 40267667. doi:10.1016/j.semarthrit.2025.152721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。